Merck & Co., Inc.’s Verquvo (vericiguat) became the first novel agent of 2021 when the US FDA approved the soluble guanylate cyclase stimulator for use in chronic heart failure patients with reduced ejection fraction on 19 January. Verquvo was joined just two days later by the second novel agent of the year, ViiV Healthcare’s antiretroviral cabotegravir, approved for HIV in two formulations as Cabenuva and Vocabria.
Bristol Myers Squibb Company’s blockbuster PD-1 inhibitor Opdivo (nivolumab) added a new renal cell carcinoma indication in combination with...






